Regulatory requirements for approval of a conventional biologic and a biosimilar are different. The biosimilar approval pathway has a more extensive analytical development phase compared to a biologic, whereas the pre-clinical/clinical pharmacology/clinical studies efforts are more extensive during the development of a biologic.
IBR Inc. has longstanding experience in development of biosimilars including Head-to-Head Comparability studies in accordance with regulations (EMA, FDA, ICH).
Our Biosimilar Services
IBR Inc. is capable to support your biosimilar project from Quality Target Product Profile, QTPP to Head-to-Head Comparability studies (quality, non-clinical and clinical studies) including equivalence testing and lot to lot consistency.
Within the Quality Target Product Profile, QTPP phase, IBR Inc. can support:
- Method development and validation
- Analysis of stress and non-stress samples of Originator
- Evaluation of critical quality attributes, CQAs
- Risk assessment and design development
Method validation is performed according to ICH Q2 (R1) guidelines and bioassays are evaluated according to statistical and tiered approaches (e.g. EU/EMA: min-max approach and USA/FDA: 95% confidence interval approach for biologics; 90% CI for biosimilars). Tiered approaches are based on the classification of critical quality attributes and risk ranking relevant to clinical outcome, that determine what type of testing is required for comparison.
IBR Inc. also supports Head-to-Head Comparability of Originator and Biosimilar with:
1. Comparative quality studies
Functional: biological/pharmacological activity
Analytical: physical/chemical properties (e.g. long term stability)
2. Comparative non-clinical studies
3. Comparative clinical studies
Pharmacokinetic/pharmacodynamics and Efficacy/Safety/Immunogenicity
Submit a Question or Request
Simply fill out the form below and a member of our team will follow up with you shortly.